ClinicalTrials.gg
Active, not recruitingNCT05502341ARTISTRY-1Updated Nov 5, 2026Results posted

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

A Phase 2/3 interventional study of Bictegravir and Lenacapavir in HIV-1-infection, sponsored by Gilead Sciences. Active, not recruiting at 94 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment

Updated Oct 21, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
689
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • If plasma -1 RNA measurements in the 6 months prior to screening are available, all levels must be \< 50 copies/mL.
  • At least one documented plasma HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be \< 50 copies/mL
  • Plasma HIV-1 RNA levels \< 50 copies/mL at screening.
  • Currently receiving a complex antiretroviral (ARV) regimen due to previous viral resistance, or intolerance, or to existing single-tablet regimens (STR), and on this regimen for at least 6 months prior to the screening visit. The criteria to define a complex regimen in this study are as follows:

    • A regimen containing a boosted protease inhibitor or a nonnucleos(t)ide reverse transcriptase inhibitor (NRTI) plus at least 1 other third agent (ie, an agent from a class other than NRTIs) (eg, bictegravir/emtricitabine/tenofovir alafenamide (coformulated; Biktarvy®)(BVY) + darunavir/cobicistat, BVY + etravirine), or
    • A regimen of ≥ 2 pills/day, or a regimen requiring dosing more than once daily, or
    • A regimen containing parenteral agent(s) (excluding a complete long-acting injectable regimen, such as intramuscular cabotegravir plus rilpivirine) as well as oral agents.
  • No documented or suspected resistance to bictegravir (BIC).
  • Estimated ≥ 15 mL/min according to the formula for creatinine clearance (CLcr) who are not on renal replacement therapy.

Key Exclusion Criteria:

  • Prior use of, or exposure to, lenacapavir (LEN)
  • Active tuberculosis infection
  • Chronic virus (HBV) infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
689 participants (actual)

Study arms

  • Experimental
    Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg

    Participants will switch from their Stable Baseline Regimen (SBR) to a regimen of BIC 75 mg + LEN 25 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day pharmacokinetic (PK) oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 25 mg starting on Day 1. Participants who discontinue early or complete the Randomized Phase (RP) will have an option to continue in Extension Period (EP)

    Drug: Bictegravir · Drug: Lenacapavir

  • Experimental
    Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg

    Participants will switch from their SBR to a regimen of BIC 75 mg + LEN 50 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 50 mg starting on Day 1. Participants who discontinue early or complete the RP will have an option to continue in EP.

    Drug: Bictegravir · Drug: Lenacapavir

  • Active comparator
    Phase 2: Treatment Group 3: SBR

    Participants will continue with their SBR for up to 24 weeks. Participants who discontinue early or complete the RP will have an option to continue in EP.

    Drug: Stable Baseline Regimen

  • Experimental
    Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC

    Participants will switch from their SBR to a regimen of BIC/LEN 75mg/50mg FDC, administered orally once daily for up to 48 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC/LEN 75 mg/50 mg FDC starting on Day 1. Participants who discontinue early or complete the RP will have an option to continue in EP.

    Drug: BIC/LEN FDC

  • Active comparator
    Phase 3: Treatment Group 2: SBR

    Participants will continue with their SBR for up to 48 weeks. Participants who will discontinue early or complete the RP had an option to continue in EP.

    Drug: Stable Baseline Regimen

  • Experimental
    Phase 2/Phase 3:BIC/LEN 75/50 mg FDC

    At the end of randomized treatment, participants in Phase 2 and Phase 3 treatment groups who discontinue early or complete the RP will be given an option to enter in EP and will receive BIC/LEN 75/50 mg FDC until the drug is available in market or Gilead elects to withdraw the study. Participants in the SBR groups (Phase 2 Treatment Group 3 and Phase 3 Treatment Group 2 will also receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2 of EP).

    Drug: Lenacapavir · Drug: BIC/LEN FDC

Interventions

  • Tablets administered orally without regard to food

    Also known as: GS-9883

  • Tablets administered orally without regard to food

    Also known as: GS-6207

  • DrugBIC/LEN FDC

    Drug page: Bictegravir

    Tablets administered orally without regard to food

    Also known as: Bixlenvo™

  • DrugStable Baseline Regimen

    SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva). * Nucleos(t)ide Reverse Transcriptase Inhibitors: * Abacavir * Emtricitabine * Lamivudine * Tenofovir alafenamide * Tenofovir disoproxil fumarate * Zidovudine * Non-Nucleosite Reverse Transcriptase Inhibitors: * Delavirdine * Efavirenz * Nevirapine * Rilpivirine * Doravirine * Integrase Inhibitors: * Bictegravir * Cabotegravir * Dolutegravir * Elvitegravir * Raltegravir * Protease Inhibitors: * Atazanavir * Darunavir * Fosamprenavir * Indinavir * Lopinavir * Nelfinavir * Saquinavir * Tipranavir * Chemokine Co-receptor 5 (CCR5) Antagonist: * Maraviroc * Fusion Inhibitors: * Enfuvirtide * gp120 Attachment Inhibitor: * Fostemsavir * Anti-CD4 Monoclonal Antibodies: * Ibalizumab-uiyk

06

What researchers measure

Primary outcomes

  1. Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm

    Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the week 24 analysis window, or who did not have on-treatment HIV-1 RNA data in the week 24 analysis window and participants who discontinued study drug prior to or in the week 24 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the week 24 analysis window due to adverse event (AE) or death and have the last available on-treatment HIV-1 RNA≥ 50 copies/mL, or who discontinued study drug prior to or in the week 24 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

    Time frame: Week 24

  2. Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm

    Participants who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to AE or death and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off.

    Time frame: Week 48

Secondary outcomes

  1. Phase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm

    Participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 24 analysis window were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

    Time frame: Week 24

  2. Phase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24

    Time frame: Baseline, Week 24

  3. Phase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

    Time frame: First dose date up to Week 24

  4. Phase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State

    Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

    Time frame: At Week 16 or 24

  5. Phase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State

    Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

    Time frame: At Week 16 or Week 24

  6. Phase 2: PK Parameter: AUCtau of BIC at Steady State

    AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

    Time frame: At Week 16 or 24

  7. Phase 2: PK Parameter: AUCtau for LEN at Steady State

    AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

    Time frame: At Week 16 or Week 24

  8. Phase 2: PK Parameter: Ctrough of BIC at Steady State

    Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

    Time frame: At Week 16 or Week 24

  9. Phase 2: PK Parameter: Ctrough of LEN at Steady State

    Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

    Time frame: At Week 16 or Week 24

  10. Phase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm

    Participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively).

    Time frame: Week 48

  11. Phase 3: Change From Baseline in CD4 Cell Count at Week 48

    An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

    Time frame: Baseline, Week 48

  12. Phase 3: Percentage of Participants Experiencing TEAEs Through Week 48

    An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.

    Time frame: First dose date up to Week 48

  13. Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm

    Time frame: Week 96

  14. Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm

    Time frame: Week 144

  15. Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm

    Time frame: Week 96

  16. Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm

    Time frame: Week 144

  17. Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96

    Time frame: Baseline, Week 96

  18. Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 144

    Time frame: Baseline, Week 144

  19. Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 96

    Time frame: Week 96

  20. Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 144

    Time frame: Week 144

07

Results

Posted Oct 21, 2026

Participant flow

Participants were enrolled at study sites in South America, Oceania, North America, Europe, Asia and Africa.

Participant flow — Overall Study
MilestonePhase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mgPhase 2: Treatment Group 3: SBRPhase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDCPhase 3: Treatment Group 2: SBR
Started515225373188
Completed00000
Not completed515225373188
Withdrew: Still on study494925358177
Withdrew: Adverse event11061
Withdrew: Withdrew consent11023
Withdrew: Death01050
Withdrew: Randomized but never treated00022
Withdrew: Investigator's discretion00003
Withdrew: Lost to follow-up00002

Outcome measures

PrimaryPhase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm

Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the week 24 analysis window, or who did not have on-treatment HIV-1 RNA data in the week 24 analysis window and participants who discontinued study drug prior to or in the week 24 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the week 24 analysis window due to adverse event (AE) or death and have the last available on-treatment HIV-1 RNA≥ 50 copies/mL, or who discontinued study drug prior to or in the week 24 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
percentage of participantsPhase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mgPhase 2: Treatment Group 3: SBR
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm01.90
Statistical analysis
  • Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg vs Phase 2: Treatment Group 3: SBR · Fisher Exact · p = 1.000 · Difference in percentage: 1.9 · 95% CI -12.2 to 10.7Differences in percentages of participants between treatment groups (BIC+LEN versus SBR) and two-sided 95% confidence interval (CI) were calculated based on unconditional exact method using 2 inverted 1-sided tests.
PrimaryPhase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm

Participants who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to AE or death and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
percentage of participantsPhase 3:Treatment Group 1:BIC/LEN 75 mg/50 mg FDCPhase 3: Treatment Group 2: SBR
Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm0.81.1
Statistical analysis
  • Phase 3:Treatment Group 1:BIC/LEN 75 mg/50 mg FDC · Difference in percentage: -0.3 · 95.002% CI -2.3 to 1.8Difference in percentages of participants between treatment groups (BIC/LEN versus SBR) and two-sided 95.002% CI were constructed based on Mantel-Haenszel stratum weights and Koch variance estimator and adjusted by geographic region.
SecondaryPhase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm

Participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 24 analysis window were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm
percentage of participantsPhase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mgPhase 2: Treatment Group 3: SBR
Phase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm96.196.2100
Statistical analysis
  • Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg vs Phase 2: Treatment Group 3: SBR · Fisher Exact · p = 1.000 · Difference in percentage: -3.9 · 95% CI -13.9 to 10.7Differences in percentages of participants between treatment groups (BIC+LEN versus SBR) and two-sided 95% CIs were calculated based on unconditional exact method using 2 inverted 1-sided tests.
  • Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg vs Phase 2: Treatment Group 3: SBR · Fisher Exact · p = 1.000 · Difference in percentages: -3.8 · 95% CI -13.4 to 10.7Differences in percentages of participants between treatment groups (BIC + LEN versus SBR) and their 95% CIs were calculated based on an unconditional exact method using 2 inverted 1-sided tests.
SecondaryPhase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · cells/µL
Phase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24
cells/µLPhase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mgPhase 2: Treatment Group 3: SBR
Baseline608 ± 238.9684 ± 329.8566 ± 304.5
Change at Week 2433 ± 155.05 ± 145.343 ± 179.6
Statistical analysis
  • Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg vs Phase 2: Treatment Group 3: SBR · ANCOVA · p = 0.9893 · Difference in least squares mean: -0.5 · 95% CI -71.3 to 70.3P value, difference in least squares mean, and its 95% CI were from analysis of covariance (ANCOVA) model of change from baseline CD4 cell count with treatment as fixed effect and baseline CD4 cell count as a covariate.
  • Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg vs Phase 2: Treatment Group 3: SBR · ANCOVA · p = 0.7173 · Difference in least squares mean: -13.0 · 95% CI -84.1 to 58.1P value, difference in least squares mean, and its 95% CI were from analysis of covariance (ANCOVA) model of change from baseline CD4 cell count with treatment as fixed effect and baseline CD4 cell count as a covariate.
SecondaryPhase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

Time frame:
First dose date up to Week 24
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24
percentage of participantsPhase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mgPhase 2: Treatment Group 3: SBR
Phase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 2476.563.568.0
SecondaryPhase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State

Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

Time frame:
At Week 16 or 24
Reported as:
Mean · ng/mL
Phase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State
ng/mLPhase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg
Phase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State9400 ± 30209860 ± 3480
SecondaryPhase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State

Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

Time frame:
At Week 16 or Week 24
Reported as:
Mean · ng/mL
Phase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State
ng/mLPhase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg
Phase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State87.4 ± 77.6134 ± 101
SecondaryPhase 2: PK Parameter: AUCtau of BIC at Steady State

AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

Time frame:
At Week 16 or 24
Reported as:
Mean · h*ng/mL
Phase 2: PK Parameter: AUCtau of BIC at Steady State
h*ng/mLPhase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg
Phase 2: PK Parameter: AUCtau of BIC at Steady State143000 ± 48300154000 ± 67000
SecondaryPhase 2: PK Parameter: AUCtau for LEN at Steady State

AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

Time frame:
At Week 16 or Week 24
Reported as:
Mean · h*ng/mL
Phase 2: PK Parameter: AUCtau for LEN at Steady State
h*ng/mLPhase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg
Phase 2: PK Parameter: AUCtau for LEN at Steady State1530 ± 11002620 ± 2100
SecondaryPhase 2: PK Parameter: Ctrough of BIC at Steady State

Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

Time frame:
At Week 16 or Week 24
Reported as:
Mean · h*ng/mL
Phase 2: PK Parameter: Ctrough of BIC at Steady State
h*ng/mLPhase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg
Phase 2: PK Parameter: Ctrough of BIC at Steady State4270 ± 19304800 ± 2950
SecondaryPhase 2: PK Parameter: Ctrough of LEN at Steady State

Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

Time frame:
At Week 16 or Week 24
Reported as:
Mean · h*ng/mL
Phase 2: PK Parameter: Ctrough of LEN at Steady State
h*ng/mLPhase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg
Phase 2: PK Parameter: Ctrough of LEN at Steady State63.4 ± 43.9104 ± 83.7
SecondaryPhase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm

Participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively).

Time frame:
Week 48
Reported as:
Number · percentage of participants
Phase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
percentage of participantsPhase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDCPhase 3: Treatment Group 2: SBR
Phase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm96.093.5
Statistical analysis
  • Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC · Difference in percentage: 2.4 · 95.002% CI 1.8 to 6.6Difference in percentages of participants between treatment groups (BIC/LEN versus SBR) and two-sided 95.002% CI were constructed based on Mantel-Haenszel stratum weights and Koch variance estimator and adjusted by geographic region.
SecondaryPhase 3: Change From Baseline in CD4 Cell Count at Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

Time frame:
Baseline, Week 48
Reported as:
Mean · cells/µL
Phase 3: Change From Baseline in CD4 Cell Count at Week 48
cells/µLPhase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDCPhase 3: Treatment Group 2: SBR
Baseline665 ± 296.2629 ± 274.7
Change at Week 4818 ± 176.36 ± 166.8
Statistical analysis
  • Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC vs Phase 3: Treatment Group 2: SBR · ANCOVA · p = 0.2239 · Difference in least squares mean: 19.0 · 95% CI -11.6 to 49.5P value, difference in least square means (LSM), and its 95% CI were from ANCOVA model of change from baseline CD4 cell count with treatment as fixed effect and baseline CD4 cell count and geographic region (US vs Ex-US) as covariates.
SecondaryPhase 3: Percentage of Participants Experiencing TEAEs Through Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.

Time frame:
First dose date up to Week 48
Reported as:
Number · percentage of participants
Phase 3: Percentage of Participants Experiencing TEAEs Through Week 48
percentage of participantsPhase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDCPhase 3: Treatment Group 2: SBR
Phase 3: Percentage of Participants Experiencing TEAEs Through Week 4879.581.2
SecondaryPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Time frame:
Week 96

Results for this outcome have not been posted.

SecondaryPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Time frame:
Week 144

Results for this outcome have not been posted.

SecondaryPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Time frame:
Week 96

Results for this outcome have not been posted.

SecondaryPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Time frame:
Week 144

Results for this outcome have not been posted.

SecondaryPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96
Time frame:
Baseline, Week 96

Results for this outcome have not been posted.

SecondaryPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 144
Time frame:
Baseline, Week 144

Results for this outcome have not been posted.

SecondaryPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 96
Time frame:
Week 96

Results for this outcome have not been posted.

SecondaryPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 144
Time frame:
Week 144

Results for this outcome have not been posted.

Adverse events

Collected over All-Cause Mortality and Adverse Events: Up to 48 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg0/51 (0%)3/51 (5.9%)20/51 (39.2%)
Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg1/52 (1.9%)2/52 (3.8%)13/52 (25%)
Phase 2: Treatment Group 3: SBR0/25 (0%)2/25 (8%)5/25 (20%)
Phase 3: Treatment Group 1: BIC/ LEN 75 mg/50 mg FDC5/373 (1.3%)52/371 (14%)141/371 (38%)
Phase 3: Treatment Group 2: SBR0/188 (0%)22/186 (11.8%)70/186 (37.6%)
Most frequent serious events
Showing 10 of 96
Most frequent serious events
EventPhase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mgPhase 2: Treatment Group 3: SBRPhase 3: Treatment Group 1: BIC/ LEN 75 mg/50 mg FDCPhase 3: Treatment Group 2: SBR
Cardiac failure acuteCardiac disorders0/510/521/250/3710/186
CardiomyopathyCardiac disorders0/510/521/250/3710/186
Intracardiac thrombusCardiac disorders0/510/521/250/3710/186
CellulitisInfections and infestations0/510/521/251/3710/186
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/510/521/251/3711/186
ThrombophlebitisVascular disorders0/510/521/250/3710/186
GastroenteritisInfections and infestations1/510/520/250/3710/186
Muscular weaknessMusculoskeletal and connective tissue disorders1/510/520/250/3710/186
Balance disorderNervous system disorders1/510/520/250/3710/186
AnxietyPsychiatric disorders1/510/520/250/3710/186
Most frequent other events
Most frequent other events
EventPhase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mgPhase 2: Treatment Group 3: SBRPhase 3: Treatment Group 1: BIC/ LEN 75 mg/50 mg FDCPhase 3: Treatment Group 2: SBR
Upper respiratory tract infectionInfections and infestations2/512/521/2534/37124/186
DiarrhoeaGastrointestinal disorders5/512/521/2522/37111/186
NasopharyngitisInfections and infestations4/510/520/2526/37117/186
Covid-19Infections and infestations4/512/522/2518/3716/186
HypertensionVascular disorders1/514/521/2520/3716/186
HeadacheNervous system disorders2/512/520/2528/3714/186
CoughRespiratory, thoracic and mediastinal disorders3/511/520/2518/37111/186
ConstipationGastrointestinal disorders3/512/520/2511/3715/186
ArthralgiaMusculoskeletal and connective tissue disorders3/511/520/2519/3718/186

Baseline characteristics

The Safety Analysis Set included all participants who took at least 1 dose of any study drug in Treatment Groups 1 and 2 in Phase 2 , or Treatment Group 1 in Phase 3, or continued with their SBR in Treatment Group 3 in Phase 2 and Treatment Group 2 in Phase 3.

Age, Categorical
Age, Categorical(Participants)Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mgPhase 2: Treatment Group 3: SBRPhase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDCPhase 3: Treatment Group 2: SBRTotal
<=18 years000000
Between 18 and 65 years333820256127474
>=65 years1814511559211
Age, Continuous
Age, Continuous(years)Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mgPhase 2: Treatment Group 3: SBRPhase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDCPhase 3: Treatment Group 2: SBRTotal
Mean61 ± 9.360 ± 8.958 ± 6.960 ± 9.359 ± 10.260 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mgPhase 2: Treatment Group 3: SBRPhase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDCPhase 3: Treatment Group 2: SBRTotal
Female13746436124
Male384521307150561
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mgPhase 2: Treatment Group 3: SBRPhase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDCPhase 3: Treatment Group 2: SBRTotal
White293420260124467
Black or African American181656433136
Not Collected000191736
Asian22016929
Other or More Than One Race20010214
American Indian or Alaska Native000112
Native Hawaiian or Other Pacific Islander000101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mgPhase 2: Treatment Group 3: SBRPhase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDCPhase 3: Treatment Group 2: SBRTotal
Not Hispanic or Latino434221270128504
Hispanic or Latino7948042142
Not Collected110211639
Region of Enrollment
Region of Enrollment(Participants)Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mgPhase 2: Treatment Group 2: BIC 75 mg + LEN 50 mgPhase 2: Treatment Group 3: SBRPhase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDCPhase 3: Treatment Group 2: SBRTotal
United States41381913470302
Canada794421981
Germany000351247
Argentina000311344
Australia221251242
Spain000251439
Italy000251136
France000181634
United Kingdom00019928
Taiwan000549
South Africa000426
Dominican Republic021115
Puerto Rico110215
South Korea000314
Japan000213
08

Study locations

94 sites
09

References and documents

Publications

  • Ph2 PK data was included as part of the 2024 HIV-G presentation: https://hivglasgow.org/wp-content/uploads/2025/02/P049_Arora.pdf
  • Orkin C, Ruane PJ, Hedgcock M, Gaultier C, Losso MH, Trottier B, Lutz T, O'Reilly M, Bloch M, Slim J, Ramgopal M, Sokhela S, Mounzer K, Tsai HC, Santana Bagur J, Zhang X, Aizen K, Price K, Margot N, Montezuma-Rusca JM, Sklar P, Rhee M, Cahn P; ARTISTRY-1 Study Group. Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial. Lancet. 2026 Mar 28;407(10535):1249-1258. doi: 10.1016/S0140-6736(26)00307-7. Epub 2026 Feb 25. PubMed 41763229 ↗
  • Arora P, Hindman JT, West S, Ling J, Palaparthy R, Marathe DD. The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a Phase 1, open-label, drug-drug interaction study. Antimicrob Agents Chemother. 2026 Jan 7;70(1):e0078125. doi: 10.1128/aac.00781-25. Epub 2025 Nov 28. PubMed 41313173 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2022 to primary completion in Sep 2025, 37 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2028 → Dec 2029, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2022
First posted
Aug 16, 2022
StartActual
Aug 16, 2022
Primary completionActual
Sep 29, 2025
CompletionEst.
Dec 2029was Jul 2028
Results first posted
Oct 21, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 21, 2026
Study completion
Jul 2028→Dec 2029
Oct 21, 2026
Interventions
Arm changed Phase 2: Bictegravir (BIC) 75 mg + Lenacapavir (LEN) 25 mg→Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg; Phase 2: BIC 75 mg + LEN 50 mg→Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg; Phase 3: BIC/LEN 75 mg/50 mg Fixed-dose Combination (FDC)→Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC. Arms added: Phase 2: Treatment Group 3: SBR·Phase 3: Treatment Group 2: SBR·Phase 2/Phase 3:BIC/LEN 75/50 mg FDC; arms removed: Phase 2: Stable Baseline Regimen (SBR)·Phase 3: Stable Baseline Regimen
Oct 21, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedPhase 2: ProportionPercentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA-defined) Defined Snapshot AlgorithmTime frame: Week 24
  • EditedPhase 3: ProportionPercentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 48
Oct 21, 2026
Publications
Results publication added: Ph2 PK data was included as part of the 2024 HIV-G presentation: https://hivglasgow.org/wp-content/uploads/2025/02/P049_Arora.pdf
Oct 21, 2026
Secondary outcomes
16 edited, 3 added, 1 description edited
What changed in the outcomes
  • EditedPhase 2: ProportionPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 24
  • EditedPhase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24Time frame: Baseline, Week 24
  • EditedPhase 2: Percentage of Participants Experiencing Treatment-emergentEmergent Adverse Events (AEsTEAEs) Through Week 24Time frame: First dose date up to Week 24
  • EditedPhase 2: Pharmacokinetic (PK) Parameter: Cmax offor Bictegravir (BIC) and Lenacapavir (LEN) at Steady StateTime frame: Day 1 up to Week 24 → At Week 16 or 24
  • EditedPhase 2: PK Parameter: AUCtau of BIC and Cmax for Lenacapavir (LEN) at Steady StateTime frame: Day 1 up to Week 24 → At Week 16 or Week 24
  • EditedPhase 2: PK Parameter: CtauAUCtau of BIC and LEN at Steady StateTime frame: Day 1 up to Week 24 → At Week 16 or 24
  • EditedPhase 3: ProportionPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 48
  • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): ProportionPercentage of Participants from With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 96
  • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): ProportionPercentage of Participants from With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 144
  • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): ProportionPercentage of Participants from With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 96
  • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): ProportionPercentage of Participants from With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 144
  • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96Time frame: Baseline, Week 96
  • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 144Time frame: Baseline, Week 144
  • EditedPhase 3: Percentage of Participants Experiencing Treatment-emergent AEsTEAEs Through Week 48Time frame: First dose date up to Week 48
  • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): ProportionPercentage of Participants from Experiencing Treatment-emergent AEsTEAEs Through Week 96Time frame: Week 96
  • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): ProportionPercentage of Participants from Experiencing Treatment-emergent AEsTEAEs Through Week 144Time frame: Week 144
  • AddedPhase 2: PK Parameter: AUCtau for LEN at Steady StateTime frame: At Week 16 or Week 24
  • AddedPhase 2: PK Parameter: Ctrough of BIC at Steady StateTime frame: At Week 16 or Week 24
  • AddedPhase 2: PK Parameter: Ctrough of LEN at Steady StateTime frame: At Week 16 or Week 24
  • DescriptionPhase 3: Change From Baseline in CD4 Cell Count at Week 48: how it is measured was reworded
Oct 21, 2026
Title
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)
Oct 21, 2026
Show all 2 updates
  1. Nov 5, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details
  2. Oct 21, 2026
    Results posted
    Publications Results publication added: Ph2 PK data was included as part of the 2024 HIV-G presentation: https://hivglasgow.org/wp-content/uploads/2025/02/P049_Arora.pdf
    Study completion Jul 2028→Dec 2029
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedPhase 2: ProportionPercentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA-defined) Defined Snapshot AlgorithmTime frame: Week 24
    • EditedPhase 3: ProportionPercentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 48
    Secondary outcomes 16 edited, 3 added, 1 description edited
    What changed in the outcomes
    • EditedPhase 2: ProportionPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 24
    • EditedPhase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24Time frame: Baseline, Week 24
    • EditedPhase 2: Percentage of Participants Experiencing Treatment-emergentEmergent Adverse Events (AEsTEAEs) Through Week 24Time frame: First dose date up to Week 24
    • EditedPhase 2: Pharmacokinetic (PK) Parameter: Cmax offor Bictegravir (BIC) and Lenacapavir (LEN) at Steady StateTime frame: Day 1 up to Week 24 → At Week 16 or 24
    • EditedPhase 2: PK Parameter: AUCtau of BIC and Cmax for Lenacapavir (LEN) at Steady StateTime frame: Day 1 up to Week 24 → At Week 16 or Week 24
    • EditedPhase 2: PK Parameter: CtauAUCtau of BIC and LEN at Steady StateTime frame: Day 1 up to Week 24 → At Week 16 or 24
    • EditedPhase 3: ProportionPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 48
    • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): ProportionPercentage of Participants from With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 96
    • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): ProportionPercentage of Participants from With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 144
    • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): ProportionPercentage of Participants from With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 96
    • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): ProportionPercentage of Participants from With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 144
    • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96Time frame: Baseline, Week 96
    • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 144Time frame: Baseline, Week 144
    • EditedPhase 3: Percentage of Participants Experiencing Treatment-emergent AEsTEAEs Through Week 48Time frame: First dose date up to Week 48
    • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): ProportionPercentage of Participants from Experiencing Treatment-emergent AEsTEAEs Through Week 96Time frame: Week 96
    • EditedPhase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): ProportionPercentage of Participants from Experiencing Treatment-emergent AEsTEAEs Through Week 144Time frame: Week 144
    • AddedPhase 2: PK Parameter: AUCtau for LEN at Steady StateTime frame: At Week 16 or Week 24
    • AddedPhase 2: PK Parameter: Ctrough of BIC at Steady StateTime frame: At Week 16 or Week 24
    • AddedPhase 2: PK Parameter: Ctrough of LEN at Steady StateTime frame: At Week 16 or Week 24
    • DescriptionPhase 3: Change From Baseline in CD4 Cell Count at Week 48: how it is measured was reworded
    Interventions Arm changed Phase 2: Bictegravir (BIC) 75 mg + Lenacapavir (LEN) 25 mg→Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg; Phase 2: BIC 75 mg + LEN 50 mg→Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg; Phase 3: BIC/LEN 75 mg/50 mg Fixed-dose Combination (FDC)→Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC. Arms added: Phase 2: Treatment Group 3: SBR·Phase 3: Treatment Group 2: SBR·Phase 2/Phase 3:BIC/LEN 75/50 mg FDC; arms removed: Phase 2: Stable Baseline Regimen (SBR)·Phase 3: Stable Baseline Regimen
    Title Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05502341
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 16, 2022
Start date
Aug 16, 2022
Primary completion
Sep 29, 2025
Completion
Dec 2029 (estimated)
Results posted
Oct 21, 2026
Last update
Nov 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Lenacapavir

Start the discussion